TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech ...

TD Cowen analyst Dan Brennan reinstated coverage of Tempus AI (TEM) with a Buy rating and price target of $74, up from $58, following the ...

TD Cowen reaffirmed their buy rating on shares of Tempus AI (NASDAQ:TEM – Free Report) in a research note published on Wednesday, Marketbeat Ratings reports. TD Cowen currently has a $74.00 price ...

TD Cowen reinitiated coverage on Tempus AI Inc (NASDAQ:TEM) with a Buy rating, increasing the price target to $74 from a previous target. The stock, currently trading at $61.85, has shown remarkable ...

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free ...

Up about 12%, Tempus AI (NASDAQ:TEM) has been explosive. Helping, its volume just spiked to 18.6 million shares, as compared ...

Multiple executives at Tempus AI Inc. executed significant share sales totaling $20.3 million between Feb. 4-7, according to ...

William Blair downgraded Tempus AI (TEM) to Market Perform from Outperform without a price target The firm cites valuation for the downgrade ...

The bank had suspended its rating and price target for Tempus during its $600 million acquisition of Ambry Genetics due to TD Securities' involvement in the deal.

Tempus AI, known for its AI-driven precision medicine,... Tuesday - Analysts at TD Cowen have initiated coverage on Tempus AI Inc (NASDAQ:TEM) stock with a Buy rating and have set a price target ...